International Liver Surgery Outcomes Study (LiverGroup)
International Study on the Outcomes of Liver Surgery - LiverGroup.Org
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Zaragoza, Spain, 50009
- University of Zaragoza, Spain
-
-
-
-
-
London, United Kingdom, NW3 2QG
- Royal Free Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All indications (including benign and living donor resections)
- All co-morbidities
- Open, laparoscopic or robotic
- Single wedge resections to extended liver resections
- Single or two-stage hepatectomies
- Procedures with liver volume enhancement such as PVE, PVL, ALPPS.
- Resections involving cold perfusion (ex-situ and ante-situ)
- There are no exclusion criteria as related to indication, age or comorbidities.
Exclusion Criteria:
- Liver transplantation
- Imaging-guided liver ablation techniques alone
- Liver biopsies
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Liver surgery
Any type of liver surgery
|
All indications (including benign and living donor resections), all co-morbidities, open, laparoscopic or robotic, single wedge resections to extended liver resections, single or two-stage hepatectomies, procedures with liver volume enhancement such as portal vein embolization (PVE), portal vein ligation (PVL), "Associating Liver Partition and Portal vein Ligation for Staged hepatectomy" (ALPPS), resections involving cold perfusion (ex-situ and ante-situ)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality rate
Time Frame: From operation until 90 days postoperatively
|
Death
|
From operation until 90 days postoperatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complication rate
Time Frame: From operation until 90 days postoperatively
|
Postoperative complications according the the Clavien-Dindo classification, the "liver Failure, Ascites, Bile leakage, Infection, Bleeding" (FABIB) liver specific classification, as well as the novel Comprehensive Complications Index® (CCI® ).
|
From operation until 90 days postoperatively
|
|
Liver failure rate
Time Frame: From operation until 90 days postoperative
|
Posthepatectomy liver failure will be assessed according to the FABIB Classification, the "International Study Group of Liver Surgery" (ISGLS) criteria as well as the 50-50 criteria up to 90 days postoperatively.
|
From operation until 90 days postoperative
|
|
Hospital stay
Time Frame: From operation until discharge from the hospital or up to 90 days postoperatively.
|
The length of hospital stay is defined as the duration of hospitalization from the day of the operation until the day of discharge from the hospital.
|
From operation until discharge from the hospital or up to 90 days postoperatively.
|
|
Re-hospitalisation rate
Time Frame: From operation until 90 days postoperatively
|
Readmission to any hospital
|
From operation until 90 days postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Massimo Malagò, MD, PhD, Royal Free Hospital, London, UK
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- v.1.3.2011.11.30
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.